Delirium Market

The global Delirium Market is valued at USD 193.4 Million in 2024 and is projected to reach a value of USD 298.7 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 4.2% between 2025 and 2035. The market is driven by an increasing aging population, enhanced methods for identifying and diagnosing conditions, and advancements in technology.

Key Highlights

• Based on the Type, Hypoactive category accounted for significant market share in 2024
• In 2024, Diagnosis dominated the market with largest market share of 62.3%
• By End user, Hospitals dominated the market with significant market share
• North America dominated the market with 41.2% market share in 2024

Type Overview

​The Type segment is divided into Hyperactive, Hypoactive, Mixed. The Hypoactive segment held the dominant share in 2024, accounting for significant market share.

The increasing recognition of hypoactive delirium, characterized by reduced motor activity and lethargy, as a critical condition that requires effective management. The growing awareness among healthcare professionals regarding the complexities and challenges associated with hypoactive delirium has led to a surge in demand for specialized diagnostic tools and treatment options tailored to this segment. Additionally, advancements in technology, such as the integration of artificial intelligence and remote monitoring solutions, have further facilitated the diagnosis and management of hypoactive delirium, drove innovation and expanding the market.

Diagnosis and treatment Overview

The diagnosis and treatment segment is divided into Diagnosis and Treatment. The diagnosis segment dominated the market with 62.3% market share in 2024.

The growth of diagnosis segment is attributed to the integration of artificial intelligence and machine learning algorithms, which are transforming diagnostic methods by providing more efficient and objective evaluations. The increasing focus on early detection and intervention is driving investment in research and development, creating a vibrant environment for diagnostic innovations in the delirium market, ultimately enhancing patient care and outcomes.

Regional Overview

In 2024, the North America captured 41.2% of the revenue share.

North America Delirium market is driven by an aging population and an increase in chronic diseases. Delirium is now more widely recognized as a critical aspect of patient treatment. Developments in the diagnosis and treatment of delirium are being fueled by the regions robust healthcare system and state-of-the-art medical research. To enhance the diagnosis and treatment of delirium, hospitals and other healthcare facilities across North America are developing training programs, adopting specialized protocols, and utilizing cutting-edge technologies.

Asia Pacific region is anticipated to grow at fastest rate during the forecast period driven by increasing healthcare spending, rapidly advancing infrastructure, rising awareness of delirium, and a growing population. China is forecasted to have the largest market share in the region, with India emerging as the fastest-growing Delirium market.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Key Trends

• Technological Advancements: Innovations such as machine learning and artificial intelligence (AI) are playing a key role in delirium diagnosis and management. Devices like Ceribell’s EEG-based system are revolutionizing how delirium is detected, enabling real-time monitoring and early intervention
• Pharmaceutical Developments: The approval of long-acting injectable antipsychotics like UZEDY and ABILIFY ASIMTUFII highlights the increasing focus on pharmaceutical treatments for delirium. These drugs offer new options for patients with complex health needs, including those with schizophrenia and bipolar disorder
• Focus on Prevention and Early Detection: Healthcare providers are emphasizing the importance of early detection and prevention of delirium in high-risk populations, such as elderly patients in intensive care units (ICUs). This has led to the development of new protocols and technologies aimed at reducing the incidence of delirium

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

The increasing aging population is a key factor propelling the growth of the Delirium market

As the global population shifts towards a higher proportion of older adults, the incidence of delirium rises. According to the World Health Organization (WHO), the global population aged 60 and older is expected to grow from 1 billion in 2020 to 1.4 billion by 2030, and reach 2.1 billion by 2050. Additionally, the number of people aged 80 and above will increase by 426 million between 2020 and 2050. Older individuals are more vulnerable to delirium due to factors like existing health conditions, cognitive decline, multiple medications, and frequent hospitalizations. Delirium risk is further increased by age-related physiological changes, such as neurotransmitter imbalances and diminished cognitive function.

Rise of telemedicine and digital health solutions

Telemedicine and remote monitoring significantly improve the management of delirium, especially for patients who live in underserved or rural areas who may find it difficult to get to medical institutions. By use of remote consultations, these technologies provide prompt interventions and early diagnosis and identification of delirium symptoms through routine evaluations. Healthcare practitioners can enhance patient outcomes by creating personalized treatment plans based on real-time data through the facilitation of a multidisciplinary approach. Furthermore, by avoiding hospital readmissions, telemedicine may lower healthcare expenditures by offering patients and caregivers support networks and educational materials.

Competitive Landscape

The Delirium market is marked by the presence of several key players and innovative products. Companies such as Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries are leading advancements in this field. Otsukas ABILIFY ASIMTUFII (aripiprazole) and Tevas UZEDY (risperidone) have both gained FDA approval for the treatment of schizophrenia and delirium, highlighting the growing focus on managing delirium through pharmaceutical interventions.

The key players in the global Delirium market include - Otsuka Pharmaceutical Co. Ltd among others.

Recent Market Developments

FDA Approves Otsukas ABILIFY ASIMTUFII for Schizophrenia, Delirium, and Bipolar I Disorder Maintenance Therapy

• In April 2023, Otsuka Pharmaceutical Co., Ltd. (Japan) received approval from the US Food and Drug Administration (FDA) for ABILIFY ASIMTUFII (aripiprazole). This medication is approved for the treatment of schizophrenia and delirium, as well as for maintenance monotherapy in individuals with bipolar I disorder. Furthermore, it is effective in managing delirium symptoms

FDA Grants Approval to Tevas UZEDY, a Long-Acting Injectable for Schizophrenia and Delirium Treatment

• In April 2023, the FDA approved UZEDY (risperidone), developed by Teva Pharmaceutical Industries. UZEDY is a long-acting injectable antipsychotic used to treat schizophrenia and delirium in adults. It is particularly beneficial for physically ill patients by reducing the behavioral and cognitive symptoms of delirium

Ceribells EEG-Based Device Receives FDA Breakthrough Designation for Delirium Detection

• In September 2022, Ceribell, Inc. (US) received FDA breakthrough device designation for its Ceribell system, which is designed to treat delirium. This device uses machine learning to analyze EEG signals, enabling the detection of delirium

The global Delirium market can be categorized as Type, Diagnosis and treatment, End-User and Region.